{
  "docId": "019de077-5087-71ae-b0e8-0abfd1317859",
  "docSlug": "b6fff97596ca7cba1b2ee8405a1dc7cd",
  "documentTitle": "AstraZeneca | Results Presentation Deck | 38 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 25,
  "pageCount": 38,
  "prevPage": 24,
  "nextPage": 26,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 1,
  "notes": "The slide uses a three-column layout to categorize growth drivers, with a footer highlighting the $80bn revenue goal.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de077-5087-71ae-b0e8-0abfd1317859/25",
  "deckHref": "/decks/019de077-5087-71ae-b0e8-0abfd1317859",
  "deckJsonHref": "/decks/019de077-5087-71ae-b0e8-0abfd1317859.json",
  "deckAnchorHref": "/decks/019de077-5087-71ae-b0e8-0abfd1317859#slide-25",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.94,
        "x": 0.03,
        "y": 0.82
      },
      "kind": "callout",
      "text": "Pipeline momentum supports ambition to achieve $80bn in Total Revenue by 2030",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c7b2bb4e-4b40-408c-8912-7282d1c5c976",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.28,
        "x": 0.66,
        "y": 0.312
      },
      "kind": "list",
      "text": "Disruptive technologies: Cell therapy, ADC, IO bispecifics, Weight management",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "359f058a-9b03-4f47-bded-96cf87b78c4e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.28,
        "x": 0.36,
        "y": 0.312
      },
      "kind": "list",
      "text": "Key NME opportunities: baxdrostat, camizestrant, Dato-DXd, eneboparatide",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e686b34e-7647-4f77-b15b-d9966219df21",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.28,
        "x": 0.06,
        "y": 0.312
      },
      "kind": "list",
      "text": "Indication expansion: Enhertu, Imfinzi, Fasenra, Truqap",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e7d40714-dc54-4171-b745-2ef22c9263b4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.03,
        "y": 0.93
      },
      "kind": "source-note",
      "text": "1. NME defined as new molecular entities that are not currently approved medicines. Collaboration partners: Daiichi Sankyo (Enhertu and Dato-DXd); Amgen (Tezspire). Appendix: Glossary.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "de4be3d2-80fa-44d1-836c-09432d2d9f7a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.94,
        "x": 0.03,
        "y": 0.08
      },
      "kind": "title",
      "text": "AstraZeneca – catalyst rich path through 2025, with potential to unlock significant value through 2030 and beyond",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f7e93935-4323-4140-b1da-97004e25a63f",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "7313effe-cea4-4dc4-a48b-26879fc0646e",
      "evidence": "The slide contains list/bullet points outlining key NME opportunities and indication expansions.",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 25,
      "from": 24,
      "beatId": "f9b6df1c-80e7-4a2e-b4d3-cbd9062fb8ed",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Satisfaction",
      "beatSlug": "monroes-sequence-satisfaction",
      "evidence": "The CEO's closing remarks provide a satisfying conclusion, highlighting the company's pipeline momentum and strategic ambitions.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 26,
      "from": 25,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "759013e5-ff1b-4c5c-bc9a-b1a6ff2cd73b",
      "evidence": "The presentation implies that failure to achieve its revenue targets would be a missed opportunity, but does not explicitly discuss the cost of inaction.",
      "position": 0,
      "objective": "What would happen if AstraZeneca failed to achieve its revenue targets?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}